Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lipocine SOARS on oral testosterone data despite FDA concerns

This article was originally published in Scrip

Executive Summary

Top-line results from the pivotal Phase III SOAR trial of Lipocine's oral testosterone product LPCN 1021 in hypogonadal men with low testosterone (Low T) show that it met its primary endpoint of getting serum hormone levels back to normal. Lipocine expects to file a new drug application (NDA) with the US FDA in the second half of 2015.


Related Content

AUA 2016: Studies Suggest Safety Ahead Of Lipocine's Oral Testosterone PDUFA


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts